Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 28:5:364.
doi: 10.3389/fgene.2014.00364. eCollection 2014.

Epigenetic modulation in the treatment of atherosclerotic disease

Mikaela M Byrne  1 , Ross T Murphy  2 , Anthony W Ryan  1
Affiliations
Review

Epigenetic modulation in the treatment of atherosclerotic disease

Mikaela M Byrne et al. Front Genet. .

Abstract

Cardiovascular disease is the single largest cause of death in the western world and its incidence is on the rise globally. Atherosclerosis, characterized by the development of atheromatus plaque, can trigger luminal narrowing and upon rupture result in myocardial infarction or ischemic stroke. Epigenetic phenomena are a focus of considerable research interest due to the role they play in gene regulation. Epigenetic mechanisms such as DNA methylation and histone acetylation have been identified as potential drug targets in the treatment of cardiovascular disease. miRNAs are known to play a role in gene silencing, which has been widely investigated in cancer. In comparison, the role they play in cardiovascular disease and plaque rupture is not well understood. Nutritional epigenetic modifiers from dietary components, for instance sulforaphane found in broccoli, have been shown to suppress the pro-inflammatory response through transcription factor activation. This review will discuss current and potential epigenetic therapeutics for the treatment of cardiovascular disease, focusing on the use of miRNAs and dietary supplements such as sulforaphane and protocatechuic aldehyde.

Keywords: DNA methyltransferase inhibition; atherosclerosis; cardiovascular disease; epigenetic targeting agents; histone deacetylase inhibition; microRNA.

PubMed Disclaimer

References

    1. Abifadel M., Varret M., Rabès J.-P., Allard D., Ouguerram K., Devillers M., et al. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 154–156. 10.1038/ng1161 - DOI - PubMed
    1. Alexy T., James A. M., Searles C. D. (2014). Shear sensitive microRNAs and atherosclerosis. Biorheology 51 147–158. 10.3233/BIR-140657 - DOI - PubMed
    1. Arrowsmith C. H., Bountra C., Fish P. V., Lee K., Schapira M. (2012). Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11 384–400. 10.1038/nrd3674 - DOI - PubMed
    1. Baccarelli A., Rienstra M., Benjamin E. J. (2010a). Cardiovascular epigenetics: basic concepts and results from animal and human studies. Circ. Cardiovasc. Genet. 3 567–573. 10.1161/CIRCGENETICS.110.958744 - DOI - PMC - PubMed
    1. Baccarelli A., Wright R., Bollati V., Litonjua A., Zanobetti A., Tarantini L., et al. (2010b). Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 21 819–828. 10.1097/EDE.0b013e3181f20457 - DOI - PMC - PubMed

LinkOut - more resources